3.76
-0.08(-2.08%)
Currency In USD
| Previous Close | 3.84 |
| Open | 3.84 |
| Day High | 3.86 |
| Day Low | 3.66 |
| 52-Week High | 7.08 |
| 52-Week Low | 2.61 |
| Volume | 328,534 |
| Average Volume | 1.18M |
| Market Cap | 477.19M |
| PE | -47 |
| EPS | -0.08 |
| Moving Average 50 Days | 4.54 |
| Moving Average 200 Days | 4.38 |
| Change | -0.08 |
If you invested $1000 in Organogenesis Holdings Inc. (ORGO) since IPO date, it would be worth $385.64 as of February 11, 2026 at a share price of $3.76. Whereas If you bought $1000 worth of Organogenesis Holdings Inc. (ORGO) shares 5 years ago, it would be worth $274.45 as of February 11, 2026 at a share price of $3.76.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Organogenesis Announces Initiation of Biologics License Application for ReNu®
GlobeNewswire Inc.
Dec 23, 2025 9:05 PM GMT
Initial modules submitted to FDA under rolling review; final modules expected in the first half of 2026CANTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on t
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
GlobeNewswire Inc.
Dec 15, 2025 9:25 PM GMT
Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the dev
Organogenesis Applauds CMS’s Significant Step In Payment Reform
GlobeNewswire Inc.
Nov 03, 2025 6:10 PM GMT
With evidence-based portfolio including technologies in each FDA category, we believe we are best positioned in the skin substitutes market for 2026 and beyondCANTON, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORG